Neuroimaging Core

神经影像核心

• 批准号: 10628507
• 负责人: PETER Thornton FOX
• 金额: $ 93.83万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-15 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10628507
• 关键词: Age Years; Alzheimer' s Disease; Alzheimer' s disease related dementia; Anosmia; Archives; Biological Markers; Blood flow; Brain; COVID-19; COVID-19 survivors; COVID-19 test; Clinical; Communities; Data; Data Analyses; Dementia; Disease; Electronic Health Record; Enrollment; Evaluation; Excision; Functional Magnetic Resonance Imaging; Genetic; Genetic Variation; Image; Impaired cognition; Incidence; Individual; Infection; Liquid substance; Longevity; Magnetic Resonance Imaging; Medial; Meta-Analysis; Metabolic syndrome; Morphologic artifacts; Motion; Neuronal Dysfunction; Participant; Pathway interactions; Patients; Phase; Polymerase Chain Reaction; Population; Post-Acute Sequelae of SARS-CoV-2 Infection; Process; Prospective, cohort study; Protocols documentation; Quality Control; Recording of previous events; Research; Risk; Risk Factors; Running; SARS-CoV-2 infection; SARS-CoV-2 positive; Sampling; Serum; Severities; Site; Smoking; South Texas; Structure; Surface; Survivors; System; Temporal Lobe; Testing; Visual; Woman; analysis pipeline; apolipoprotein E-4; archive data; arm; biobank; blood oxygen level dependent; cohort; comorbidity; data acquisition; data archive; data exploration; data management; data sharing; data standards; dementia risk; expectation; experience; follow-up; glucose metabolism; human old age (65+); image archival system; indexing; interest; men; neuroimaging; pandemic disease; recruit; statistics

The ISAVRAD U19 proposes a five-site, two-arm (patients and controls), longitudinal (3 assessments/subject) study enrolling 4,300 individuals. All 5 enrollment sites are experienced in recruiting genetically homogenous cohorts. Pilot data of various types are provided in the respective projects and cores. Participants will be men and women (~50:50 ratio) who are > 60 years of age and either have a history of polymerase chain reaction (PCR) test positive COVID-19 infection (75% of sample) or have no history of COVID-19 (25% of sample). Evaluations will be performed upon enrollment, 18 months, and 36 months. Evaluations will comprise a standardized data acquisition battery including assessment of clinical status and serum sampling for fluid-based biomarkers and genetics. Neuroimaging will be conducted at enrollment and at 18 months. Data acquisition, preprocessing, archiving and sharing – both within the U19 and with the scientific community at large – will be overseen by the Administrative, Clinical, Neuroimaging, and Data Management & Statistics Cores of the U19. The Neuroimaging Core will manage neuroimaging acquisition (2 assessments/subject), quality control, harmonization, data archiving and data sharing at all five study sites. Image acquisition, quality control and harmonization strategies will emulate those of ADNI3 and Mark VCID supplemented by team expertise. Minimal data preprocessing will use pipelined approaches both volumetric and surface-based. Surface-based analyses will emulate Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) protocols, with the expectation that other large studies of the post-acute sequelae of COVID-19 (PASC) will emerge and that ENIGMA community will embrace the challenge of ongoing data exploration both meta-analytic and mega- analytic. Aim 1: Image Acquisition, Harmonization and Quality Control. Structural MRI and functional MRI images will be acquired at all five study sites. Structural MRI acquisitions will emulate those of ADNI3, UKBioBank, Lifespan HCP, MarkVCID and GOBS. Functional MRI acquisitions will emulate the latest GOBS. The Neuroimaging Core will coordinate acquisition across sites, including harmonization and quality control. Aim 2: Image Preprocessing and Pipeline analytics. The Neuroimaging Core will perform post-acquisition quality control, image preprocessing (artifact removal, motion correction, etc.), and run widely used volumetric and surface-based pipeline analyses. Blood-oxygen-level-dependent (BOLD)-based indices of neuronal dysfunction will be cross validated with glucose metabolism and blood flow. Aim 3: Image Archiving, Access Control, and Sharing. Anonymized raw and processed volumetric and surfaced- based images and image-derived data (region of interest [ROI] values) and visual-inspection scores will be archived in the XNAT system. Spreadsheet-compatible data will be provided to the Data Management and Statistics Core.

ISAVRAD U19 提出了五点、两臂（患者和对照）、纵向（3 个评估/受试者） 研究招募了 4,300 名个体，所有 5 个招募地点在招募基因同质性方面都有丰富的经验。 各个项目和核心参与者均提供了各种类型的试点数据。 以及年龄 > 60 岁并且有聚合酶链反应史的女性（~50:50 比例） (PCR) COVID-19 感染检测呈阳性（75% 的样本）或没有 COVID-19 病史（25% 的样本）。 评估将在注册后、18 个月和 36 个月内进行。 标准化数据采集电池，包括临床状态评估和基于液体的血清采样 将在入组时和 18 个月时进行生物标志物和遗传学检查。 预处理、存档和共享——无论是在 U19 内部还是与整个科学界——都将 由 U19 的行政、临床、神经影像以及数据管理和统计核心监督。 神经影像核心将管理神经影像采集（每个受试者 2 次评估）、质量控制、 所有五个研究中心的图像采集、质量控制和数据协调、数据归档和数据共享。 协调策略将效仿 ADNI3 和 Mark VCID 的策略，并辅以最少的团队专业知识。 数据预处理将使用基于体积和基于表面的分析的流水线方法。 将模拟通过荟萃分析增强神经影像遗传学 (ENIGMA) 协议， 预计其他关于 COVID-19 急性后遗症（PASC）的大型研究将会出现，并且 ENIGMA 社区将迎接持续进行元分析和大型数据探索的挑战 分析的。 目标 1：结构 MRI 和功能 MRI 图像的图像采集、协调和质量控制。 在所有五个研究中心获得的结构 MRI 数据将效仿 ADNI3、UKBioBank、Lifespan 的数据。 HCP、MarkVCID 和 GOBS 采集将模拟最新的 GOBS。 将协调跨站点的采购，包括协调和质量控制。 目标 2：图像预处理和管道分析。神经成像核心将执行采集后质量。 控制、图像预处理（伪影去除、运动校正等），并运行广泛使用的体积和 基于表面的管道分析基于血氧水平（BOLD）的神经功能障碍指数。 将与葡萄糖代谢和血流进行交叉验证。 目标 3：图像存档、访问控制和共享，原始和处理后的体积和表面图像。 基于图像和图像衍生数据（感兴趣区域 [ROI] 值）和目视检查分数将 存档在 XNAT 系统中的电子表格兼容数据将提供给数据管理和 统计核心。